More about

Bleeding

News
May 14, 2020
4 min read
Save

Ticagrelor monotherapy reduces bleeding risk after PCI regardless of DES platform

Ticagrelor monotherapy reduces bleeding risk after PCI regardless of DES platform

Among patients who underwent PCI with a drug-eluting stent and were prescribed dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy reduced bleeding risk compared with continued DAPT regardless of DES type, according to results from the TWILIGHT-SYNERGY study.

News
April 27, 2020
2 min read
Save

Dabigatran with P-glycoprotein inhibitors may increase bleeding risk in AF, normal kidney function

Dabigatran with P-glycoprotein inhibitors may increase bleeding risk in AF, normal kidney function

Patients with nonvalvular atrial fibrillation and normal kidney function had increased bleeding risk with dabigatran when used alongside P-glycoprotein inhibitors diltiazem and verapamil, according to a retrospective comparative effectiveness cohort study published in JAMA Network Open.

News
April 07, 2020
1 min read
Save

In ACS, nearly 8% of bleeding events linked to new cancer diagnosis

In ACS, nearly 8% of bleeding events linked to new cancer diagnosis

Patients with ACS who had a bleeding event after hospital discharge had an increased risk for a subsequent cancer diagnosis within the first 6 months, according to a study published in The American Journal of Cardiology.

News
March 29, 2020
5 min read
Save

Oral anticoagulation alone reduces bleeding after TAVR vs. dual therapy

Oral anticoagulation alone reduces bleeding after TAVR vs. dual therapy

The incidence of serious bleeding after transcatheter aortic valve replacement was lower in patients assigned oral anticoagulation alone compared with those assigned oral anticoagulation and clopidogrel, according to data from the POPULAR-TAVI trial presented at the American College of Cardiology Scientific Session.

News
March 16, 2020
2 min read
Save

Dual therapy may confer less major bleeding vs. triple therapy in AF, PCI

Dual therapy may confer less major bleeding vs. triple therapy in AF, PCI

A meta-analysis of randomized controlled trials published in the Annals of Internal Medicine showed that dual therapy was associated with lower risk for major bleeding in patients with nonvalvular atrial fibrillation after PCI compared with triple therapy.

News
March 09, 2020
3 min read
Save

Apixaban may confer less stroke, systemic embolism, bleeding vs. rivaroxaban

Apixaban may confer less stroke, systemic embolism, bleeding vs. rivaroxaban

In a retrospective cohort study, patients with atrial fibrillation who were treated with apixaban experienced lower incidence of ischemic stroke, systemic embolism and bleeding compared with patients who received rivaroxaban.

News
March 06, 2020
2 min read
Save

Physicians inappropriately favor discontinuing PPIs in high risk upper GI bleeding cases

Survey results revealed most internists perceived proton pump inhibitors were linked with numerous adverse events and recommended their discontinuation even in patients who are high risk for upper gastrointestinal bleeding.

News
February 07, 2020
2 min read
Save

GI bleeding may increase cancer risk in AF with anticoagulation

GI bleeding may increase cancer risk in AF with anticoagulation

Bleeding in the lower gastrointestinal tract increased risk for incident colorectal cancer in patients with atrial fibrillation who were treated with oral anticoagulants, according to a study published in the European Heart Journal.

News
January 13, 2020
2 min read
Save

Post-PCI ticagrelor does not lower MACE risk vs. clopidogrel in cohort study

Post-PCI ticagrelor does not lower MACE risk vs. clopidogrel in cohort study

Among patients with ACS who underwent PCI and received an outpatient prescription for ticagrelor or clopidogrel, ticagrelor was not associated with a significant reduction in risk for MACE, and those who received ticagrelor had more major bleeding and dyspnea, according to data from a population-based cohort study published in JAMA Internal Medicine.

News
November 17, 2019
4 min read
Save

TWILIGHT-ACS: Ticagrelor monotherapy beneficial in PCI for ACS

TWILIGHT-ACS: Ticagrelor monotherapy beneficial in PCI for ACS

PHILADELPHIA — Among patients with ACS who underwent PCI, ticagrelor monotherapy reduced bleeding risk compared with dual antiplatelet therapy, with no additional ischemic risk, according to new data from the TWILIGHT study presented at the American Heart Association Scientific Sessions.

View more